B-form DNA minor groove (B-DNA minor groove)

The B-form DNA minor groove is a structural feature of the standard right-handed DNA double helix, characterized by a narrower and shallower opening compared to the major groove (Wikipedia, 2023). It serves as a critical site for the binding of various proteins, including transcription factors and architectural proteins that regulate gene expression and DNA packaging (PubMed, PMID: 11375571). In therapeutic contexts, the minor groove is a primary target for small molecules known as minor groove binders (MGBs), which often prefer AT-rich sequences due to the specific arrangement of hydrogen bond donors and acceptors (NIH, PubChem). These interactions can disrupt essential cellular processes such as DNA replication and transcription, making the minor groove a significant target for anticancer, antibacterial, and antiparasitic agents (StatPearls, 2023). For instance, drugs like trabectedin bind the minor groove to induce DNA damage and interfere with transcription-coupled repair, while others like pentamidine exploit minor groove binding for antimicrobial activity (FDA, Yondelis Label). Despite their efficacy, drugs targeting the DNA minor groove often face challenges related to systemic toxicity and potential mutagenicity due to their interaction with the fundamental genetic material of the host (Journal of Medicinal Chemistry, 2014).

Other names

DNA minor grooveMinor groove of B-DNAMinor groove

Drugs targeting the B-form DNA minor groove typically function by binding non-covalently to the floor of the groove, often preferring AT-rich sequences where they can form specific hydrogen bonds and van der Waals contacts (PubMed, PMID: 11375571). This binding can competitively displace transcription factors, inhibit the movement of RNA and DNA polymerases, or induce structural changes in the DNA helix that prevent proper gene expression and replication (NIH, PubChem). Some agents, such as trabectedin, go further by forming covalent adducts with the DNA, leading to double-strand breaks and the recruitment of DNA repair machinery that ultimately triggers apoptosis in malignant cells (FDA, 2015).